
Enzene Cuts Biomanufacturing Costs to $80 Million with New NeX Model
A conventional biologics plant demands an investment of up to $400 million, a price tag often prohibitive for emerging markets. Enzene is challenging this status quo with NeX, a turnkey partnership model that leverages continuous manufacturing to slash capital requirements to between $60 million and $80 million per facility.























